Skip to Content

Steglujan (ertugliflozin / sitagliptin) Disease Interactions

There are 3 disease interactions with Steglujan (ertugliflozin / sitagliptin):


DPP-4 inhibitors (Includes Steglujan) ↔ pancreatitis

Severe Potential Hazard, Low plausibility. Applies to: Pancreatitis

There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors. These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk. Patients should be observed for signs and symptoms of pancreatitis during treatment. If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.


Ertugliflozin (Includes Steglujan) ↔ renal impairment

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

The use of ertugliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis. The use of ertugliflozin in patients with moderate renal impairment did not have improvement in glycemic control, and had increased risks for renal impairment, renal-related adverse reactions and volume depletion adverse reactions; therefore, its use is not recommended in this population. No dosage adjustment or increased monitoring is needed in patients with mild renal impairment. Renal function should be evaluated prior to initiating treatment with ertugliflozin and periodically thereafter.


DPP-4 (Includes Steglujan) ↔ renal dysfunction

Moderate Potential Hazard, High plausibility. Applies to: Renal Dysfunction

It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors. Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment. Linagliptin will not require a dose adjustment per manufacturer's information. Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses. However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.

Steglujan (ertugliflozin / sitagliptin) drug interactions

There are 674 drug interactions with Steglujan (ertugliflozin / sitagliptin)

Steglujan (ertugliflozin / sitagliptin) alcohol/food interactions

There is 1 alcohol/food interaction with Steglujan (ertugliflozin / sitagliptin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.